Blindness Claims Rock Common GLP-1 Drug

A Georgia nurse says a popular weight-loss shot stole the sight in one eye after drug makers failed to warn her it was even a risk.

Story Snapshot

A Hartwell, Georgia woman claims she went blind in one eye after taking the GLP-1 drug Wegovy.
Her case is part of a growing wave of lawsuits tying GLP-1 weight-loss drugs to a rare eye “stroke” called NAION.
Drug labels in Europe now warn about this vision risk, but U.S. labels for semaglutide drugs still do not.
Scientists see warning signs in recent studies, yet say the link between GLP-1 drugs and blindness is not fully proven.

Georgia Patient’s Story And The Lawsuit Behind It

Television station WSB-TV profiled Diane Worth, a former nurse practitioner from Hartwell, Georgia, who says she began using the weight-loss drug Wegovy in February 2025 and soon suffered sudden vision loss in her right eye. Doctors later diagnosed her with non-arteritic anterior ischemic optic neuropathy, or NAION, a rare condition sometimes called an eye stroke because blood flow to the optic nerve is reduced. Worth says no one told her the drug could be linked to blindness and that she saw no such warning on the materials she received in the United States.

Worth has now joined a lawsuit that claims GLP-1 drugs such as Wegovy, Ozempic, and similar injections caused NAION and that their makers failed to warn patients and doctors about the risk. Her story is not isolated. Law firms around the country are signing up clients who say they took semaglutide or other GLP-1 drugs and later experienced black spots, blurred vision, or sudden blindness in one eye that did not improve. Many of these patients say they would have made a different choice if labels or doctors had clearly explained even a rare chance of permanent vision loss before starting the medication.

What NAION Is And How It Connects To Weight-Loss Drugs

NAION is the most common sudden optic nerve problem in adults over age 50 and often leads to lasting damage. In this condition, blood supply to the front part of the optic nerve drops, and patients may wake up to find part or all of the vision in one eye gone, usually without pain. Recent research has raised alarms by finding higher NAION rates among people using semaglutide, the active ingredient in Ozempic and Wegovy. One observational study reported that patients on semaglutide had more than a sevenfold increased risk of NAION compared with those on other treatments, with about one extra case per 7,000 patients per year.

Other studies and reviews echo that there may be an elevated relative risk, especially for people with diabetes or obesity, yet they stress that the absolute number of cases remains very low. A large meta-analysis in 2026 estimated roughly a two- to threefold increased risk of NAION among semaglutide users but still only around eight cases per 100,000 people each year, compared with seven per 100,000 on placebo. Some randomized clinical trial data, which are usually more reliable, have not shown a clear increase in NAION events among people on GLP-1 drugs versus placebo, which adds to the scientific debate. Researchers say more work is needed to prove whether the drugs truly cause NAION or simply appear alongside other health factors that raise risk.

From Safety Signal To Mass Litigation And Regulatory Split

As case reports and early studies came out, lawsuits quickly followed. By late 2025, federal judges had grouped vision-loss cases involving Ozempic, Wegovy, Saxenda, and similar drugs into a multidistrict litigation in Pennsylvania, a special court process used when many people make similar claims against the same companies. Legal trackers say the number of blindness cases in that litigation has jumped from a few dozen to more than one hundred by mid-2026, with more being filed in state courts as well. Plaintiffs argue that Novo Nordisk and Eli Lilly knew or should have known about the emerging NAION risk but did not put clear warnings on U.S. labels or properly alert doctors.

Regulators overseas have moved faster than those in the United States. In June 2025, the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide and recommended updating product information for Ozempic, Wegovy, and Rybelsus. United Kingdom drug regulators also issued safety advisories warning that semaglutide can increase NAION risk. By contrast, American experts and agencies have taken a more cautious approach, pointing to conflicting studies and saying evidence does not yet confirm a direct cause-and-effect relationship. This gap leaves U.S. patients like Worth wondering why warnings exist on European packaging while American users often learn about the risk only after something goes wrong.

Why This Fight Resonates With A Distrustful Public

The GLP-1 blindness lawsuits land at a time when many Americans feel the health system serves drug companies and political insiders more than ordinary patients. On one side, people frustrated by rising medical costs and long-term safety worries see this as another case where corporations chased profit while regulators dragged their feet. They point to research signals, foreign warnings, and rapid lawsuit growth as signs that elites knew about possible dangers but did not act until public pressure mounted. For them, a nurse in Georgia losing her sight after a heavily marketed “miracle” drug fits a larger story of a system that has stopped putting people first.

Georgia woman part of lawsuit claiming link between GLP-1 weight loss drugs and blindness https://t.co/NwBlduqCGv pic.twitter.com/BodsgLDVg5

— WSB-TV (@wsbtv) July 20, 2026

On the other side, doctors and scientists warn that fear could push some patients to suddenly stop drugs that help control diabetes and weight, which carry their own serious risks. They urge careful, informed decisions instead of panic, stressing that NAION appears very rare and that obesity and diabetes themselves can harm vision. Yet many patients say they are not getting that full picture from government and industry, and that it should not take a lawsuit or a foreign safety notice to learn that a medicine might, in rare cases, take their sight. The tension between public distrust and slow-moving science will likely shape how these GLP-1 cases unfold in court and in society.